[go: up one dir, main page]

BR112015009229A2 - composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada - Google Patents

composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada

Info

Publication number
BR112015009229A2
BR112015009229A2 BR112015009229A BR112015009229A BR112015009229A2 BR 112015009229 A2 BR112015009229 A2 BR 112015009229A2 BR 112015009229 A BR112015009229 A BR 112015009229A BR 112015009229 A BR112015009229 A BR 112015009229A BR 112015009229 A2 BR112015009229 A2 BR 112015009229A2
Authority
BR
Brazil
Prior art keywords
stem cell
platelets
vitro
generating
gene expression
Prior art date
Application number
BR112015009229A
Other languages
English (en)
Other versions
BR112015009229B1 (pt
Inventor
a wilcox David
L Haberichter Sandra
Original Assignee
Platelet Targeted Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Platelet Targeted Therapeutics Llc filed Critical Platelet Targeted Therapeutics Llc
Publication of BR112015009229A2 publication Critical patent/BR112015009229A2/pt
Publication of BR112015009229B1 publication Critical patent/BR112015009229B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo tratamento tendo como alvo plaqueta a presente divulgação se refere a composições e métodos tendo como alvo a expressão de genes exógenos para as plaquetas. em particular, a presente divulgação se refere a tratamento de hemofilia e outras doenças e condições tendo como alvo expressão de agentes exógenos (por exemplo, fatores de coagulação) para plaquetas.
BR112015009229-2A 2012-10-24 2013-10-24 Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada BR112015009229B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
US61/717,951 2012-10-24
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Publications (2)

Publication Number Publication Date
BR112015009229A2 true BR112015009229A2 (pt) 2017-11-14
BR112015009229B1 BR112015009229B1 (pt) 2021-07-20

Family

ID=50545271

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009229-2A BR112015009229B1 (pt) 2012-10-24 2013-10-24 Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada

Country Status (12)

Country Link
US (4) US9982034B2 (pt)
EP (2) EP3859004A1 (pt)
JP (2) JP2016501515A (pt)
KR (1) KR101819803B1 (pt)
BR (1) BR112015009229B1 (pt)
CA (1) CA2888982C (pt)
DK (1) DK2912186T3 (pt)
ES (1) ES2854754T3 (pt)
IL (1) IL238417B (pt)
PL (1) PL2912186T3 (pt)
WO (1) WO2014066663A1 (pt)
ZA (1) ZA201502945B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322800A4 (en) 2015-07-13 2019-05-01 University of Utah Research Foundation PROCESS FOR THE PRODUCTION OF RED BLOOD BODIES AND BLOOD PLATES IN VITRO AND USES THEREOF
US12060576B2 (en) 2018-01-05 2024-08-13 Stellular Bio, Inc. Compositions and methods for producing megakaryocytes
EP3861102A4 (en) * 2018-10-05 2022-07-13 University of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
US20200224164A1 (en) 2018-11-30 2020-07-16 Cellphire, Inc. Platelets as delivery agents
EP3937631A4 (en) * 2019-03-13 2023-01-04 Cellphire Inc. DOG PLALETLET PREPARATIONS
BR112021021984A2 (pt) 2019-05-03 2022-03-03 Cellphire Inc Materiais e métodos para produzir produtos de sangue
US20210308185A1 (en) 2020-02-04 2021-10-07 Cellphire, Inc. Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
US11701388B2 (en) 2019-08-16 2023-07-18 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0914178B1 (en) 1996-06-18 2003-03-12 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE234649T1 (de) 1996-12-20 2003-04-15 Alza Corp Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
IL136488A0 (en) 1997-12-02 2001-06-14 Powderject Vaccines Inc Transdermal delivery of particulate vaccine compositions
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
CA2450125A1 (en) * 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
IL160132A0 (en) * 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
WO2003030934A2 (en) 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1815021A2 (en) * 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
ES2600879T3 (es) 2009-11-13 2017-02-13 Grifols Therapeutics Inc. Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
US20120225028A1 (en) * 2011-03-02 2012-09-06 Moshe Cohen Compositions and methods for mobilization of stem cells

Also Published As

Publication number Publication date
US20150344541A1 (en) 2015-12-03
EP2912186A1 (en) 2015-09-02
IL238417B (en) 2019-07-31
ES2854754T3 (es) 2021-09-22
US9982034B2 (en) 2018-05-29
JP2018161152A (ja) 2018-10-18
KR20150069017A (ko) 2015-06-22
IL238417A0 (en) 2015-06-30
PL2912186T3 (pl) 2021-06-14
US10294291B2 (en) 2019-05-21
CA2888982A1 (en) 2014-05-01
JP2016501515A (ja) 2016-01-21
ZA201502945B (en) 2016-11-30
EP3859004A1 (en) 2021-08-04
HK1211986A1 (en) 2016-06-03
US20240270822A1 (en) 2024-08-15
US20180009874A1 (en) 2018-01-11
KR101819803B1 (ko) 2018-01-17
EP2912186B1 (en) 2021-01-06
DK2912186T3 (da) 2021-02-22
JP6975105B2 (ja) 2021-12-01
BR112015009229B1 (pt) 2021-07-20
WO2014066663A1 (en) 2014-05-01
CA2888982C (en) 2020-07-21
US20190270791A1 (en) 2019-09-05
EP2912186A4 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
DOP2014000233A (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
MX2018012556A (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
BR112015022770A2 (pt) métodos e materiais para diferenciação hematoendotelial de células-tronco pluripotentes humanas sob condições definidas
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
MX367605B (es) Composiciones de nanopartículas lipídicas y métodos para administración de arnm.
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
MX387333B (es) Inhibidores de glucosilceramida sintasa.
DOP2013000240A (es) Composiciones y métodos para transferencia de energía mitocondrial de línea germinal autóloga
AR083162A1 (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
MY171710A (en) Culture medium composition, and method for culturing cell or tissue using said composition
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
DOP2012000281A (es) Composiciones farmaceuticas y metodos para su elaboracion
BR112014031424A2 (pt) tratamento de células pluripotentes
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
BR112016004510A2 (pt) composições bioativas deriváveis de concentrados de plaquetas e métodos para preparar e usar as mesmas
CA2775299C (en) Thrombin isolated from blood and blood fractions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2013, OBSERVADAS AS CONDICOES LEGAIS.